お知らせ • Jun 11
Mycodern S.A., Annual General Meeting, Jul 06, 2026 Mycodern S.A., Annual General Meeting, Jul 06, 2026, at 10:00 Central European Standard Time. お知らせ • Nov 12
Mycodern S.A. to Report Q3, 2025 Results on Nov 14, 2025 Mycodern S.A. announced that they will report Q3, 2025 results on Nov 14, 2025 お知らせ • Aug 26
Mycodern S.A. to Report Fiscal Year 2024 Results on Sep 30, 2025 Mycodern S.A. announced that they will report fiscal year 2024 results on Sep 30, 2025 Reported Earnings • Aug 20
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: zł2.24m (up 254% from 2Q 2023). Net loss: zł572.9k (loss narrowed 61% from 2Q 2023). お知らせ • Jul 30
Mycodern S.A. to Report Fiscal Year 2023 Results on Sep 20, 2024 Mycodern S.A. announced that they will report fiscal year 2023 results on Sep 20, 2024 Reported Earnings • May 20
First quarter 2024 earnings released First quarter 2024 results: Revenue: zł1.36m (up 66% from 1Q 2023). Net loss: zł1.94m (flat on 1Q 2023). New Risk • Apr 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł993k free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 66% per year over the past 5 years. Revenue is less than US$1m (zł2.7m revenue, or US$674k). Minor Risks Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (€14.2m market cap, or US$15.2m). New Risk • Apr 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł993k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł993k free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 66% per year over the past 5 years. Revenue is less than US$1m (zł2.7m revenue, or US$695k). Minor Risk Market cap is less than US$100m (€15.2m market cap, or US$16.5m). お知らせ • Feb 03
Mycodern S.A. to Report Q4, 2023 Results on Feb 14, 2024 Mycodern S.A. announced that they will report Q4, 2023 results on Feb 14, 2024